Introduction
In the last decades, two cannabinoid receptor (CBR) subtypes have been identified, cloned, expressed, and functionally investigated (Matsuda et al. 1990; Munro et al. 1993) . The CB 1 R has primarily been observed in central and peripheral nervous structures (Tsou et al. 1998) , whereas the CB 2 R is predominantly found in immune cells (Berdyshev 2000; Galiegue et al. 1995; Munro et al. 1993; Schatz et al. 1997) . Interestingly, (endo)cannabinoid-mediated effects independent of the CB 1 R and the CB 2 R have been described (Oz 2006; Pertwee 2005) . Such (endo)cannabinoid responses may involve orphan receptors GPR119 and GPR55; in addition, transient receptor potential (TRP) channels are also a matter of debate (Brown 2007; Rao and Kaminski 2006b; Clapham et al. 2005 ).
Both the CB 1 R and the CB 2 R belong to the G-proteincoupled receptor superfamily and primarily couple to pertussis toxin-sensitive and adenylyl cyclase-inhibitory G i/o -proteins (Childers and Deadwyler 1996; Felder et al. 1995; Hofmann et al. 2000; Gkoumassi et al. 2007 ). Enhancement of cAMP production through linkage to G sproteins, however, has been reported as well (Bonhaus et al. 1998; Gkoumassi et al. 2007; Glass and Felder 1997) . Recently, we have shown that both CBR subtypes are present in human bronchial epithelial (16HBE14o − ) cells and are functionally coupled to adenylyl cyclase. We found that, in response to the endocannabinoid virodhamine and the synthetic cannabinoid CP55,940, the CB 2 R signaling pathway is predominant and inhibits adenylyl cyclase and the cellular release of interleukin-8. Following pretreatment with pertussis toxin, increased accumulation of cAMP became apparent, however, which was mediated by CB 1 R. Interestingly, the synthetic cannabinoid CP55,940 evoked such 16HBE14o
− cell responses less efficiently compared to the endocannabinoid virodhamine (Gkoumassi et al. 2007 ). Indeed, CP55,940 acts as a non-selective receptor agonist (Burkey et al. 1997; Thomas et al. 2007 ), whereas virodhamine acts as a partial agonist on the CB 1 R and as a full agonist on the CB 2 R (Porter et al. 2002) .
Next to the modulation of adenylyl cyclase, (endo) cannabinoid-induced changes in intracellular calcium ([Ca 2+ ] i ) have been investigated in various cell types. We reported that the phytocannabinoid Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and the synthetic cannabinoid CP55,940 induced Ca 2+ influx and [Ca 2+ ] i mobilization in DDT 1 MF-2 smooth muscle cells, processes being dependent on the CB 1 R (Filipeanu et al. 1997 ) and on the release of arachidonic acid (Begg et al. 2001; Demuth et al. 2005) . Recent reports indicated that Δ 9 -THC, but not CP55,940, induced Ca 2+ alterations in resting T cells independent of CB 1 R and CB 2 R (Rao et al. 2004; Rao and Kaminski 2006a) , but dependent on Ca 2+ influx through the TRP channel TRPC1 (Rao and Kaminski 2006b) . Interestingly, the endocannabinoid anandamide has been shown to activate the TRP family member TRPV1 (Clapham et al. 2005) .
In bronchial epithelial cells, changes in intracellular calcium are importantly involved in the regulation of mucus secretion, cytokine production, surfactant secretion, and ciliary beat frequency (Conway et al. 2003; Sakamoto et al. 2007; Haller et al. 1998; Lansley et al. 1992) . Exposure of epithelial cells to cannabinoids may represent a result of marijuana smoke (Δ 9 -THC) or endogenously released cannabinoids like virodhamine and anandamide (Porter et al. 2002) . However, the effects of (endo)cannabinoids on intracellular calcium alterations in bronchial epithelial cells have not been described yet. Therefore, we aimed in the current study to identify and to characterize alterations in intracellular calcium evoked by (endo)cannabinoids in human bronchial epithelial (16HBE14o − ) cells. As it has been reported that the newly identified (endo)cannabinoid virodhamine is present in two to nine times higher concentrations in peripheral tissues than the classical (endo)cannabinoid anandamide (Porter et al. 2002) , we studied the effect of virodhamine in comparison to Δ 9 -THC and CP55,940. We demonstrated that Δ 9 -THC, CP55,940, and low concentrations of virodhamine induced [Ca 2+ ] i increases in 16HBE14o − cells involving mobilization and subsequent capacitive calcium entry (CCE) mechanisms, whereas high virodhamine concentrations induced [Ca 2+ ] i increases predominantly through non-CCE (NCCE) pathways.
Materials and methods

Chemicals and drugs
All chemicals were of analytical grade and obtained from Sigma (Zwijndrecht, The Netherlands), unless stated otherwise. -THC, virodhamine and arachidonic acid, were prepared in ethanol, shielded from light, and stored at −20°C. SR141716A and SR144528 were dissolved in dimethyl sulfoxide (DMSO) and stored at room temperature. Lanthanum (III) chloride, gadolinium (III) chloride, and nickel (II) chloride solutions were prepared freshly in distilled water. Stock solution of quinacrine [6-chloro-9-(4-diethylamino-1-methylbutylamino)-2-methoxyacridine dihydrochloride] was prepared in DMSO and stored at 4°C. Thapsigargin was dissolved in DMSO and stored at −20°C. Capsazepine was dissolved in ethanol and stored at −20°C. Ruthenium red was dissolved in distilled water and stored at room temperature. The antibody directed to TRPC6 was a gift from Dr. Alexander Dietrich (Hofmann et al. 2000; Dietrich et al. 2003) , and the antibody directed to TRPV1 was from Biomol (Exeter, UK).
Cell culture
The immortal human bronchial epithelial cell line 16HBE14o − (Cozens et al. 1994 ) was a kind gift from Dr. D. C. Gruenert (University of Vermont, Burlington VT, USA). Cells were grown at 37°C in minimum essential medium (MEM), supplemented with 10% fetal bovine serum, penicillin (50 µg/ml), streptomycin (50 µg/ml), and L-glutamine (2 mM) in fibronectin/collagen coated flasks to near confluency in an atmosphere of 5% CO2/95% O 2 . For arachidonic acid release studies, cells were plated into 9.6 cm 2 six well plates. All culture media and supplements were obtained from Life Technologies (Breda, The Netherlands). Cell culture dishes were from Costar (Badhoevedorp, The Netherlands), and flasks were from Greiner (Alphen a/d Rijn, The Netherlands).
Intracellular Ca
2+ measurements Intracellular [Ca 2+ ] was measured using Fura-2 fluorometry as reported previously (Demuth et al. 2005) . Briefly, cells were trypsinized and loaded in suspension with 3μM Fura-2 acetoxymethylester at 37°C for 45 min in the dark. Fluorescence was measured at 37°C. When used, receptor antagonists (SR141716A and SR144528 1µM) and channel inhibitors (capsazepine 10µM, ruthenium red 20µM, Gd 3+ 1µM, La 3+ 10µM, Ni 2+ 1 mM) were added 10 min prior to the agonist.
RNA isolation and RT-PCR
Total RNA was isolated using the RNeasy minikit (Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions. RNA samples were purified with a RQ1 RNAse-free DNAse to remove genomic DNA contaminations. Subsequently, RNA (1μg) was transcribed into cDNA using the Promega RT system kit. PCR reactions were performed using the Promega RT-PCR Core system kit (Leiden, The Netherlands), according to the manufacturer's instructions, using a Mastercycler Gradient (Eppendorf, Hamburg, Germany). For the detection TRP channels the following primer pairs were obtained from Invitrogen (Leek, The Netherlands): TRPC1 (forward): 5′-GTG CGG GAG GTG AAG GAG GAG AAT-3′; TRPC1 (reverse): 5′-CTG CAT GGG GCT TGG GTA GAG ATA-3′; TRPC6 (forward): 5′-ATG ATA TGG GCT GAA TGT AAA GA-3′; TRPC6 (reverse): 5′-TCA AAG TAG GAA AAC CAG AG-3′; TRPV1 (forward): 5′-CTA ACT CCA GGC CAC CTC CA-3′; TRPV1 (reverse): 5′-GCC ATG TTG CGT CTC TCG AT-3′; TRPV4 (forward): 5′-TAC TAT CGA GGT CAG ACA GC-3′; TRPV4 (reverse): 5′-CCG CAG CAG TTC ATT GAT GG-3′. With these primers, the amplified gene fragments were 463, 752, 562, and 678 bp, respectively. PCR reactions that comprised of a denaturing step at 94°C for 5 min was followed by amplification for 30 cycles at 94°C, 1 min; annealing temperature, 1 min; 72°C, 1 min; with final extension at 72°C for 10 min. The annealing temperature used for TRPC1 was 52°C, 60°C for TRPC6, and 58°C for TRPV1 and TRPV4. The amplified product (2µl) was separated on a 2% agarose gel, and the DNA was visualized by ethidium bromide. A 100 bp ladder (MBI Fermentas, St. Leon-Rot, Germany) was used as DNA marker. Restriction analysis was performed with EcoRI for TRPC1 (expected fragments 335 and 128), with HindIII for TRPC6 (expected fragments 342 and 410), with PstI for TRPV1 (expected fragments 328 and 234), and HincII for TRPV4 (expected fragments 477 and 201; Sigma, Zwijndrecht, The Netherlands) for 2 h at 37°C according to the manufacturer's protocol.
Immunoblot analysis
Western blot analysis was performed as described before (Gkoumassi et al. 2007; Hassock et al. 2002; Hofmann et al. 2000) . Briefly, cell lysate (corresponding to 10-15µg protein per lane) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, using 10% gel at 100 V. Proteins in the gel were transferred onto nitrocellulose membranes, which were subsequently blocked with blocking buffer (Tris-HCl 50 mM, NaCl 150 mM, Tween-20 0.1%, dried milk powder 5%) for 90 min. Membranes were incubated overnight at 4°C using 1:1,000 dilution of rabbit polyclonal antiserum raised against the C-terminal peptide VGHNKQPSIRS-SEDFHLNSFNNPP (amino acids 829-852 of hTRPC6); the rabbit polyclonal antiserum against the TRPV1 was used at a dilution of 1:200. After three washes of 10 min each, membranes were incubated with horseradish peroxidase-labeled secondary antibodies (1:3,000 in blocking buffer) for 90 min at room temperature, followed by another three washes. Antibodies were visualized by enhanced chemiluminescence.
Arachidonic acid release measurements [ 3 H]Arachidonic acid release was measured as described previously (Demuth et al. 2005; Van der Zee et al. 1995) . In short, cells were grown to confluency in 9.6 cm 2 six well plates and labeled with 0.25µCi of [ 3 H]arachidonic acid (specific activity, 60-100 Ci (2.22-3.70 TBq)/mmol) in serum-free MEM (1 ml), for 3 h at 37°C. Cells were washed once in extracellular salt solution (ECS) containing (mM): NaCl, 125; KCl, 6; MgCl 2 , 2.5; NaH 2 PO 4 , 1.2; Hepes, 20; glucose, 11; sucrose, 67; CaCl 2 , 1.2; pH7.4, twice with ECS containing 1% BSA (fatty acid-free) and once again with ECS to eliminate unincorporated radioactivity; subsequently, cells were allowed to equilibrate for 15 min, in the absence or presence of the inhibitors. Cells were stimulated with the agonist for 5 min, and the incubation was stopped by removing the ECS. [
3 H] Arachidonic acid release into the ECS was quantified using liquid-scintillation counting.
Data analysis
Values are expressed as means±standard error of the mean (SEM). Comparison of pairs of treatments was made using Student's t test. P < 0.05 was considered significant. All curves were fitted using a logistic fit four-parameter model (SigmaPlot 10, SYSTAT Software, Chicago IL, USA).
Results
To assess the effects of (endo) (Fig. 1b and c) , consisting of a relatively fast peak (transient) and a sustained plateau phase (Fig. 1a) . In the absence of extracellular Ca 2+ , a depressed transient response remained, whereas the sustained plateau phase was abrogated (Fig. 1b and c) . Analysis of the concentration-effect curves indicated pEC 50 values of 4.57 ± 0.05 (n = 6) and of 4.56 ± 0.08 (n = 5) for (Fig. 3) (Clapham et al. 2005; Demuth et al. 2005 ; Fig 3a and b) . The CCE-dependent Ca 2+ entry was inhibited by Ni 2+ ions with a pIC 50 of 2.99 ± 0.25 (Fig. 3c) . Importantly, the CP55,940-induced Ca 2+ influx was also completely blocked by the CCE inhibitor Ni 2+ , strongly pointing to the involvement of CCE in CP55,940 driven Ca 2+ influx (Fig. 4a) . Previous studies have implicated that TRPC1 is involved in CCE (Clapham et al. 2005; Sweeney et al. 2002b) and that cannabinoids induce Ca 2+ influx in part via these channels (Rao and Kaminski 2006b) . Indeed, PCR analysis revealed that mRNA for the TRP channel TRPC1 was expressed by 16HBE14o − cells (Fig. 4b) , which is in agreement with previous findings in primary HBE cells (Corteling et al. 2004 ). (Fig. 5c) . Surprisingly, the CB 1 R antagonist SR141716A further enhanced the virodhamine (30µM)-induced [Ca 2+ ] i increase, whereas the NCCE-inhibitor Gd 3+ and the TRPV1-TRPV4 inhibitor ruthenium red strongly reduced the large Ca 2+ influx component (Fig. 5b) . To further assess the potential role of CBR subtypes and Ca 2+ channels, we quantified the virodhamine-induced calcium alterations (Fig. 6 ). Both the CB 1 R antagonist SR141716A and the CB 2 R antagonist SR144528 augmented [Ca 2+ ] i increase in response to 10 and 30 μM virodhamine, suggesting an inhibitory effect of the CBRs on virodhamine-induced Ca 2+ influx. The CBR antagonists did not alter the control level of [Ca 2+ ] i (data not shown).
As (endo)cannabinoids have been implicated in the activation of the vanilloid receptor/Ca 2+ channel TRPV1 (Clapham et al. 2005) , we studied the effect of the TRPV1 antagonist capsazepine (CPZ) on the virodhamine-induced Ca 2+ influx as well. At low (10μM) virodhamine concentrations, CPZ did not alter the virodhamine-induced [Ca 2+ ] i increase (Fig. 6a) . At high (30μM) virodhamine concentrations, however, the virodhamine-induced [Ca 2+ ] i increase was sensitive to CPZ (Fig. 6b) , implying the involvement of TRPV1 channels in this response. The classical vanilloid-TRPV receptor agonist capsaicin (1-100 µM) by itself did not affect intracellular calcium concentrations (data not shown), and pretreatment with capsaicin did not significantly increase virodhamine-induced calcium alterations (P = 0.14; Fig 6a) . Interestingly, the TRPV1-TRPV4 inhibitor ruthenium red was able to reduce virodhamine (30 µM)-induced [Ca 2+ ] i increase as well (Fig. 6b) . As we observed the presence of TRPV1 and TRPV4 mRNAs and TRPV1 protein in 16HBE14o − cells (Fig. 6c and d ) and a previous study has reported the presence of the TRPV4 protein in differentiated primary HBE cells (Sidhaye et al. 2008 ), a potential role for such Ca 2+ channels in virodhamine-induced Ca 2+ influx should be envisaged as well. Almost complete inhibition of virodhamine-induced Ca 2+ influx was achieved by the NCCE inhibitors Gd 3+ and La 3+ used at low concentrations of 1 and 10µM, respectively (Fig. 6b) . In contrast, the CCE inhibitor Ni 2+ did not inhibit virodhamine-induced Ca 2+ influx, even at a concentration of 1 mM (Fig. 6b) . Collectively, these observations b mRNA expression of TRPC1 in 16HBE14o − cells. Total RNA was reverse-transcribed into cDNA, and specific fragments were amplified by PCR, separated on 2% agarose gel, and visualized with ethidium bromide. Restriction analysis, performed with EcoRI, is presented in the right lane clearly point to a role NCCE mechanisms in the calcium response induced by high virodhamine concentrations. Currently, TRPC6 channels are the only channels known to be sensitive to low concentrations of Gd 3+ and La 3+ (Clapham et al. 2005) . Indeed, in agreement with findings in primary HBE cells (Corteling et al. 2004 ), we detected both mRNA and protein of TRPC6 in 16HBE14o − cells.
Next to the 100 kDa immunoreactive positive TRPC6 band, an additional band of 73 kDa was visible, similar to the band reported before in HEK293 cells (Dietrich et al. 2003) .
Since arachidonic acid has been shown to be an important mediator in NCCE-dependent Ca 2+ entry (Demuth et al. 2005 ; Van der Zee et al. 1995; Shuttleworth and Thompson 1999) , we also investigated the release of this lipid mediator by 16HBE14o − cells upon stimulation with virodhamine. A concentration-dependent release of arachidonic acid was observed (pEC 50 = 5.19 ± 0.16), which did not increase further at concentrations above 10 μM, indicating that virodhamine-induced arachidonic acid release may be involved in NCCE (Fig. 7a) . This release was sensitive to the phospholipase A 2 inhibitor quinacrine, but insensitive to CBR antagonists (Fig. 7b) . Virodhamineinduced arachidonic acid release was, however, sensitive to capsazepine treatment, and a trend towards a decrease in arachidonic acid release was observed for ruthenium red, indicating that TRPV1 channels may be involved in these responses. Finally, to assess whether arachidonic acid could be involved in the activation of TRPV1 by virodhamine, we investigated the effects of arachidonic acid on [Ca 2+ ] i increase. Concentrations of arachidonic acid between 1 and 30μM induced a concentration-dependent [Ca 2+ ] i increase, with a pEC 50 = 5.17 ± 0.63 and a maximal Δ[Ca 2+ ] i of 97.3 ± 7.5 nM ( Fig. 8a and b ). Higher concentrations of arachidonic acid (≥100μM) induced a large, fast, and almost linear increase at high concentrations (Fig 8a) , very similar to the effects observed for the high virodhamine concentrations.
Discussion
In the present study, we report for the first time that the structurally distinct (endo)cannabinoids Δ 9 -THC, CP55,940, and virodhamine induce intracellular [Ca 2+ ] i increase driven by different mechanisms in human bronchial epithelial 16HBE14o − cells. All three compounds induce an [Ca 2+ ] i increase by Ca 2+ entry from the extracellular space, but for Δ 9 -THC, this Ca 2+ influx is subsequent to a large transient [Ca 2+ ] i mobilization and may therefore reflect a store-depletion-driven CCE mechanism. Indeed, we reported in previous studies in DDT 1 MF-2 smooth muscle cells that the Δ 9 -THC-induced Ca 2+ release from thapsigargin-sensitive intracellular stores involved the CB 1 R and subsequent CCE mechanisms (Filipeanu et al. 1997) . Interestingly, Δ 9 -THC induced an additional Ca 2+ influx in these cells independent of CB 1 R and CB 2 R. Recently, a robust Δ 9 -THC-induced Ca 2+ influx was reported in resting T cells, also independent of CB 1 R and CB 2 R (Rao and Kaminski 2006a) and at least partly mediated by TRPC1 channels (Rao and Kaminski 2006b) . While thapsigargin-sensitive CCE mechanisms are operative in 16HBE14o − cells and cellular gene transcription of TRPC1 channels was present and the involvement of TRPC1 channels in CCE mechanisms being well established (Clapham et al. 2005; Sweeney et al. 2002a) , it is reasonable to assume that subsequent to Ca 2+ release from intracellular, Δ 9 -THC-induced Ca 2+ entry may be gated through TRPC1 channels in 16HBE14o − cells indeed.
The synthetic non-selective CBR agonist CP55,940 induced only a modest and a sustained [Ca 2+ ] i mobilization.
We reported earlier that CP55,940 is also less efficacious compared to the endocannabinoid virodhamine in inhibiting cAMP accumulation and release of interleukin-8 from 16HBE14o − cells (Gkoumassi et al. 2007 ). The Ca 2+ influx induced by CP55,940 was inhibited by Ni 2+ , indicating the involvement of a CCE mechanism, possibly mediated by TRPC1 channels. Previous studies, however, showed that entry following Ca 2+ release from thapsigargin-sensitive pools in a CBR-independent manner (Chou et al. 2001) . Collectively, these studies indicate that mechanisms distinct from those in other cell types are operative in CP55,940-induced [Ca 2+ ] i increase in 16HBE14o − cells.
Remarkably, the (endo)cannabinoid virodhamine induced Ca 2+ increase at concentrations which were 150 times higher than we described previously for CBR-mediated inhibition of cAMP accumulation and interleukin-8 release from 16HBE14o − cells (Gkoumassi et al. 2007 ). This observation suggests Ca 2+ entry via CBR-independent channel activation. In support of this, changes in [Ca 2+ ] i evoked by both low and high concentrations of virodhamine were increased rather than decreased in the presence of both CB 1 R and CB 2 R antagonists, which would suggest inhibitory effects of CBRs on [Ca 2+ ] i alterations under these conditions or even aspecific actions of the CBR antagonists on cation channels (Rao et al. 2004; Rao and Kaminski 2006a; White and Hiley 1998) .
Virodhamine-induced arachidonic acid release and Ca 2+ entry showed the same concentration-dependence, suggesting that such cellular responses are driven by the same NCCE mechanisms. Receptor-independent effects by (endo)cannabinoids may be dependent on their lipophilic nature (Oz 2006) . Such processes, however, do not exclude potential physiologically important effects with regard to the activation of TRP channels, as concentrations of arachidonic acid-derivatives may reach concentrations up to 5 mM in for example human platelets, and concentrations as used in our current study are physiologically not uncommon (Brash 2001; Oz 2006) . Recent studies even indicated that higher concentrations of virodhamine are necessary for attaining the full agonist effect (Porter et al. 2002; Steffens et al. 2005; Ho and Hiley 2004) . 
